RLAY VS ANIP Stock Comparison

PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend
PerformanceTechnicalsEarningsProfitVolatilityAnalyst Price TargetsSentimentDividend

Performance

RLAY
10/100

RLAY returned -58.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ANIP
100/100

ANIP returned 45.01% in the last 12 months. Based on SPY's performance of 9.73%, its performance is above average giving it a score of 100 of 100.

Technicals

RLAY
64/100

RLAY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

ANIP
32/100

ANIP receives a 32 of 100 based on 14 indicators. 4 are bullish, 9 are bearish.

Earnings

RLAY
10/100

RLAY has missed earnings 8 times in the last 20 quarters.

ANIP
17/100

ANIP has missed earnings 6 times in the last 20 quarters.

Profit

RLAY
10/100

Out of the last 19 quarters, RLAY has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ANIP
37/100

Out of the last 20 quarters, ANIP has had 9 profitable quarters and has increased their profits year over year on 4 of them.

Volatility

RLAY
53/100

RLAY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.

ANIP
43/100

ANIP has had a lower than average amount of volatility over the last 12 months giving it a score of 43 of 100.

Analyst Price Targets

RLAY

"Analyst Price Targets" not found for RLAY

ANIP
83/100

3 analysts offer 12-month price targets for ANIP. Together, they have an average target of 48, the most optimistic target put ANIP at 48 within 12-months and the most pessimistic has ANIP at 48.

Sentiment

RLAY

"Sentiment" not found for RLAY

ANIP
69/100

ANIP had a bullish sentiment score of 68.80% across Twitter and StockTwits over the last 12 months. It had an average of 6.60 posts, 1.00 comments, and 1.00 likes per day.

Dividend

RLAY

"Dividend" not found for RLAY

ANIP
10/100

ANIP's most recent dividend was $0.01 per share, based on a share price of $53.22. It was a payout ratio of -0.78% compared to their total earnings.

All score calculations are broken down here to help you make more informed investing decisions

Relay Therapeutics, Inc. Common Stock Summary

Nasdaq / RLAY
Healthcare
Biotechnology
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

ANI Pharmaceuticals, Inc. Summary

Nasdaq / ANIP
Healthcare
Drug Manufacturers - Specialty & Generic
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.